Skip to main content
Clinical Trials/NCT03011398
NCT03011398
Enrolling By Invitation
Not Applicable

Interventional Orthopedics Foundation Patient Registry Database-A Clinical Registry of Orthobiologics Procedures

Regenexx, LLC28 sites in 3 countries50,000 target enrollmentFebruary 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Orthopedic Disorder
Sponsor
Regenexx, LLC
Enrollment
50000
Locations
28
Primary Endpoint
Change in Percent Improvement
Status
Enrolling By Invitation
Last Updated
last year

Overview

Brief Summary

The purpose of the Registry study is to observe the improvement in subject-reported clinical outcomes for percutaneous orthopedic procedures for treatment of musculoskeletal disorders.

Detailed Description

This Registry was designed to assure that the benefits and knowledge gained by studying clinical outcomes associated with the use of percutaneous orthopedic procedures outweigh the potential risks to the patients. The primary objective of this Registry is to observe the improvements in subject-reported clinical outcomes for these procedures used to treat musculoskeletal disorders. Secondary objectives include evaluating post-treatment complication, adverse events, re-injections, and surgical intervention. Patients receiving percutaneous orthopedic treatments are asked to enroll before receiving treatment and complete a set of baseline questionnaires regarding pain and functionality of the area of the body being treated (i.e. knee, shoulder, spine, etc). Follow-up outcomes are collected at 1 month, 3 months, 6 months, 12 months, 18 months, and annually 2-20 years post-injection. Subjects are withdrawn from the Registry prematurely if a surgical operation occurs.

Registry
clinicaltrials.gov
Start Date
February 2016
End Date
February 2036
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Candidates must meet ALL of the following:
  • Voluntary signature of the IRB approved Informed Consents,
  • Treated with a Regenexx procedure
  • Have a musculoskeletal condition appropriate for the procedure such as osteoarthritis or internal joint derangement; ligament or tendon injury; intervertebral disc degeneration; protrusion, extrusion, or annular tear; muscle tear

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Change in Percent Improvement

Time Frame: 1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment

Mean improvement score, where -100=100% worse from baseline and 100=100% better or improved from baseline

Secondary Outcomes

  • Oxford Hip Score(1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment)
  • Complications(1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment)
  • Number of Re-injections to treated area(1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment)
  • Number of Surgical Interventions to treated area(1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment)
  • International Knee Documentation Committee form(1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment)
  • Disabilities of the Arm, Shoulder and Hand form(1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment)
  • Pain Scale(1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment)
  • Functional Rating Index(1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment)
  • Adverse Events(1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment)
  • Lower Extremity Function Scale(1 month, 3 months, 6 months, 12 months, 18 months and annually 2-20 years post treatment)

Study Sites (28)

Loading locations...

Similar Trials